利来国际app

Fosun Pharma started its innovation and R&D in 2009 and made great progress in R&D efficiency, system construction and international influence since 2017.

By the end of 2024, the company had more than 80 projects for drugs under development (calculated by indications), including innovator drugs, biosimilars. In 2024, the company applied for 220 patents in the pharmaceutical manufacturing segment, including 3 US patents and 18 PCT applications, with 66 patents granted.

According to 2024 Annual Report
*Unit: RMB billion yuan

  • 55.54 million
    R&D investment in 2024
  • 3,047
    R&D personnel
  • 1,600+
    Personnel with master's degree or above

In China

  • 20
    Concurrent clinical trials
  • 7
    IND applications
  • 3
    NDA applications

In The United States And Australia

  • 3
    Clinical trials
  • 1
    IND application
  • 2
    IND approvals
High-tech: PCG - protein therapy, cell therapy, gene therapy, small molecule pioneering/best innovator drugs
  • Double-antibody
  • Stem cell therapy
  • mRNA therapy
  • Gene editing
Tumor/immunology, neurological disorders (chronic degeneration, stroke, etc.), chronic/metabolic diseases, infectious/rare diseases
  • Tumor/immunology
  • Central Nervous System
  • Metabolic/chronic diseases
  • Infectious/rare diseases